Renibus Therapeutics raised $110.89 million to advance veverimer, an FDA-designated orphan drug for the treatment of anti-glomerular basement membrane disease, an ultra-rare life-threatening kidney condition.
Renibus Therapeutics raised $110.89 million to advance veverimer, an FDA-designated orphan drug for the treatment of anti-glomerular basement membrane disease, an ultra-rare life-threatening kidney condition.